Recognition of Human Actions in Video

Recognition and analysis of Human actions is an important task in the area of computer vision. There are many applications of this research which include surveillance systems, patient monitoring systems, human performance analysis, con tent - based image/video retrieval/storage, virtual reality and a variety of syst ems that involve interactions between persons or interactions between person and devices, etc. The need for such system is increasing day - by - day, with the increase in number of surveillance cameras deployed in public spaces. Automated systems are required that can detect, categorize and recognize human activities and request the human attention only when necessary. In this paper, important steps of such a system are described that can robustly tracks human in various environments and recognizes their actions through image sequences acquired from a single fixed camera. The overall system consists of major th ree steps: blob extraction, feature extraction, and human action recognition. Given the sequence of images, a statistical method is demonstrated to extract the blobs and to remove the shadows and highlights in order to obtain a more accurate object silhouet te. Shape context is used to extract features in next step and at - last human action is recognized using neural networ

Histomorphological spectrum of central nervous system lesions in a tertiary care hospital

Background: Central nervous system (CNS) lesions show considerable geographic and racial variations with respect to the incidence and their pattern of distribution. CNS neoplasm account for 2% of all cancers. There has been a rapid increase in incidence of CNS tumors. Many non-neoplastic CNS lesions can clinically and radiologically mimic brain tumors and to differentiate them histopathological examination is necessary.Methods: This was a descriptive cross-sectional study of 30 cases, carried out from March 2020 to February 2021, in a tertiary health care hospital. The cases were diagnosed histopathologically and categorized according to the WHO 2021 classification.Results: The study included 30 cases. 3 (10%) of them were non-neoplastic while 27 (90%) were neoplastic with glioblastoma and diffuse astrocytoma being the most common. Overall, tumors of neuroepithelial tissue (60%) was the most common entity. Frontal lobe was the most commonly observed site in the neoplastic lesion. Headache was the most common presentation. Age range varied from 7 years to 66 years with the mean age of 32.7 years.Conclusions: The spectrum of neoplastic lesions were astrocytoma, glioblastoma, ependymoma, hemagioblastoma, medulloblastoma, meningioma, non-hodgkins lymphoma, oligodendroglioma, pitutary adenoma, schwannoma and non-neoplastic were A-V malformation, brain abscess, subdural empyema

Development and validation of dissolution method for carvedilol compression-coated tablets

The present study describes the development and validation of a dissolution method for carvedilol compression-coated tablets. Dissolution test was performed using a TDT-06T dissolution apparatus. Based on the physiological conditions of the body, 0.1N hydrochloric acid was used as dissolution medium and release was monitored for 2 hours to verify the immediate release pattern of the drug in acidic pH, followed by pH 6.8 in citric-phosphate buffer for 22 hours, to simulate a sustained release pattern in the intestine. Influences of rotation speed and surfactant concentration in medium were evaluated. Samples were analysed by validated UV visible spectrophotometric method at 286 nm. 1% sodium lauryl sulphate (SLS) was found to be optimum for improving carvedilol solubility in pH 6.8 citric-phosphate buffer. Analysis of variance showed no significant difference between the results obtained at 50 and 100 rpm. The discriminating dissolution method was successfully developed for carvedilol compression-coated tablets. The conditions that allowed dissolution determination were USP type I apparatus at 100 rpm, containing 1000 ml of 0.1N HCl for 2 hours, followed by pH 6.8 citric-phosphate buffer with 1% SLS for 22 hours at 37.0 ± 0.5 ºC. Samples were analysed by UV spectrophotometric method and validated as per ICH guidelines.O presente estudo descreve o desenvolvimento e a validação de método de dissolução para comprimidos revestidos de carvedilol. O teste de dissolução foi efetuado utilizando-se o aparelho para dissolução TDT-06T. Com base nas condições fisiológicas do organismo, utilizou-se ácido clorídrico 0,1 N como meio de dissolução e a liberação foi monitorada por 2 horas para se verificar o padrão de liberação imediata do fármaco em condições de pH baixo, seguidas por pH 6,8 em tampão cítrico-fosfato por 22 horas, para simular o padrão de liberação controlada no intestino. Avaliou-se a influência da velocidade de rotação e a concentração de tensoativo no meio. As amostras foram analisadas por método espectrofotométrico UV-visível validado, em 286 nm. O laurilsulfato sódico a 1% (SLS) mostrou-se ótimo para aumentar a solubilidade do carvedilol em pH 6,8 em tampão cítrico-fosfato. A análise da variância não mostrou diferença significativa entre os resultados obtidos a 50 e a 100 rpm. O método da dissolução discriminante foi desenvolvido com sucesso para os comprimidos revestidos de carvedilol. As condições que permitiram a determinação da dissolução foram: aparelho USP tipo I a 100 rpm, contendo 1000 mL de HCL 0,1 N por 2 horas, seguido de pH 6,8 com tampão cítrico-fosfato, com 1% de SLS por 22 horas a 37,0 ± 0,5 ºC. Amostras foram analisadas por método espectrofotométrico e validadas pelas normas ICH

A case report: remdesivir effective in the treatment of severe category COVID-19

Since the first cases were reported in December 2019, infection with the severe acute respiratory corona virus 2 (SARS-CoV-2) has become a worldwide pandemic. COVID-19 the illness caused by SARS-CoV-2 is overwhelming health care systems globally. In the absence of a proven effective therapy, current management consists of supportive care, including invasive and noninvasive oxygen support and off-label or compassionate-use therapies, including   anti-retrovirals, anti-parasitic agents, anti-inflammatory compounds, and convalescent plasma. Amongst these experimental therapies, remdesivir a broad-spectrum antiviral drug has shown some promising results. We present a successfully treated patient of severe acute respiratory illness by SARS-CoV-2 with remdesivir along with standard management protocol. Reporting a case with aim to add favoring evidence for remdesivir in the treatment of         SARS-CoV-2

Hairy cell leukemia: a rare case report

Hairy cell leukemia (HCL) is a rare chronic B-cell leukemia accounting for 2% of all the leukemias and occurs more frequently in the elderly males. The etiology is unknown but possible relationships to radiation exposure, exposure to benzene, to farm animals and to commercial herbicides and pesticides have been identified. Familial predisposition among first degree relatives has been noted. It is characterized by distinctive cytoplasmic “hair like” projections on the cell surface of lymphoid cells, pancytopenia and splenomegaly. We report a rare case of 29 year old female, farm labourer presenting with fever, fatigue and weakness for 1 month. On examination the patient had hepatomegaly, massive splenomegaly and inguinal lymphadenopathy. After peripheral smear examination diagnosis of HCL was made which was confirmed by bone marrow aspiration examination, bone marrow biopsy and immunohistochemistry (IHC)

PULSATILE RELEASE OF KETOPROFEN FROM COMPRESSION COATED TABLETS USING EUDRAGIT® POLYMERS

Objective: The objective of the present research work is to develop compression coated tablet of ketoprofen as a pulsatile release system for treatment of rheumatoid arthritis.Methods: Core tablets of ketoprofen were prepared using the wet granulation method and evaluated for appearance, hardness, friability, weight variation, thickness, disintegration time and % drug release. Core tablets were coated with Eudragit S100 and Eudragit L100 by compression coating method to achieve desired lag time. The blends of core and coating materials were evaluated for bulk density, tapped density, Hausner's ratio, % Compressibility index and angle of repose. Compression coated tablets were evaluated for appearance, hardness, friability, weight variation, thickness and % drug release.Results: Core tablets, as well as compression coated tablets, showed acceptable Pharmaco technical properties. Optimized core tablets were disintegrated within 15s due to the effectiveness of super disintegrant, sodium starch glycolate. Dissolution studies of compression coated tablets in media with different pH (1.2, 6.8, and 7.4) showed that drug release could be modulated by changing the concentration of EudragitL100 and Eudragit S100. The optimized batch exhibited 80% drug release up to 6 h with a 4 h lag time. Stability study of the optimized formulation indicated no significant change in appearance, physical parameters, drug content and drug release profile at accelerated conditions for two months.Conclusion: compression coated tablet of ketoprofen was successfully developed to achieve burst drug release after specific lag time.Keywords: Chronomodulated drug delivery, Pulsatile release, Compression coated tablets, Lag tim

Development and test analysis of Symmetric Open TEM cell

Electrical and electronic devices are constantly present in human lives, as providing communication, entertainment or transportation. Ever increasing use of power electronics equipment and communication equipment in everyday life is increasing electromagnetic pollution day by day. This pollution may degrade the performance of electronic and electrical equipment. Any RF radiation emitting devices emit Electro Magnetic (EM) radiation and without proper shielding, the radiation could be harmful to humans and other biological elements. Modernization in new generation of mobile telecommunication system, with enhanced bandwidth and power, the biological effects of electromagnetic radiation from these gadgets is a real concern to many It is necessary that all electronics equipment or systems must be constructed to ensure that any electromagnetic disturbance it generates must be constructed with inherent level of immunity to externally generated Electromagnetic disturbances. These needs to design the equipment known as TEM cell with symmetric open structure geometry to limit the amount of unwanted radiation, the shielding of critical parts, making equipment less immune to external interference

Evaluation of complication during third stage of labour at tertiary care center

Background: The objective of the present study was to determine the maternal outcome of complications of third stage of labour and to determine the risk factors and evaluate the management protocols for these complications.Methods: This is retrospective study of maternal outcome with complications of third stage of labour carried out at tertiary care centre from June 2016 to December 2019. Patients who developed any complications of third stage of labour after vaginal delivery or caesarean section were included.Results: Complications observed during third stage of labour were atonic PPH 0.82% (74 cases), traumatic PPH 0.55% (50 cases), retained placenta (including placenta accreta spectrum) 0.21% (19 cases), secondary PPH 0.03% (3 cases), uterine inversion 0.03% (3 cases) and amniotic fluid embolism 0.01% (1 case). Maximum cases were seen in 18-24 years of age group. Only 36% patients having atonic PPH responded to medical treatment, 46% patients having atonic PPH responded to conservative surgery, 18% of patients required radical surgery.Conclusions: Third stage complications are potentially life threatening. Associated conditions for third stage complication are high parity, anemia, hydramnios, multiple pregnancy, malpresentation, placenta previa, and adherent placenta. Early anticipation and early intervention with proper planning is required to reduce the maternal morbidity and mortality in third stage complication

Maternal and fetal outcome in cases of eclampsia

Background: Eclampsia refers to occurrence of generalized tonic clonic convulsions (GTCS) followed by confusion or coma during pregnancy or puerperium in patients with preeclampsia excluding other neurological conditions. Purpose of this study was to evaluate the risk factors, management protocols and determine maternal and perinatal morbidity and mortality in patients of eclampsia.Methods: This is retrospective study of 180 cases of eclampsia carried out from June 2017 to December 2019 including all the antepartum, intrapartum and postpartum cases at tertiary care centre. Immediate management was focused to control the convulsion and lower the blood pressure followed by NST and USG foetus with Doppler study.Results: In this study, 72.2% cases reported antepartum eclampsia while 27.8% cases were postpartum and overall incidence was 0.91% of total deliveries conducted during the study period. Incidence was higher in primigravida (74.4%) and below 25 years age (68.8%). Magnesium sulphate was effective in 94.4% cases. Study reports 63 normal vaginal delivery, 5 assisted vaginal delivery, 110 caesarean section and 2 women expired undelivered. There were 10 maternal deaths.Conclusions: Time interval between eclamptic seizures and initiation of therapy is an important prognostic factor affecting maternal and perinatal outcome. Public awareness regarding the importance of regular antenatal visits can help in reducing chances of development of eclampsia. Even though various drugs and methods have been tried for the treatment of eclampsia, the definitive management is the delivery of foetus after control of convulsion, hypertension and should be managed at tertiary care hospital